The group's principal activities are to develop multiple proprietary gene delivery and gene expression systems and pegylation technologies and apply our preclinical and early clinical development expertise to create novel therapeutics and improved versions of currently marketed biopharmaceuticals. the group focuses on research, preclinical development and early stage clinical development of products in several therapeutic areas including cardiovascular disorders, oncology, haematology and immunology. the group has developed synthetic gene delivery systems based on several classes of delivery enhancing materials, including polymers and lipids. the polymeric, non-condensing polymers are designed to provide efficient delivery to a variety of tissues, including muscle and solid tumors. the cationic lipids provide efficient delivery after intravenous or intratumoral administration.